Seeking Alpha
 

Actavis plc. (ACT)

- NYSE
  • Feb. 14, 2012, 9:02 AM
    More on Watson (WPI +2.2%) Q4: Net income more than quintuples to $94.8M, with earnings boosted by generic versions of Pfizer's Lipitor cholesterol treatment and J&J's Concerta ADHD drug. Watson ups its 2012 EPS guidance to $5.50-$5.80 from $5.25-$5.55 and vs. $5.60 consensus. Also ups rev forecast by $100M to $5.4B.
    | Comment!
  • Feb. 14, 2012, 7:19 AM
    Watson Pharmaceuticals (WPI): Q4 EPS of $1.77 beats by $0.02. Revenue of $1.55B (+81.5% Y/Y) in-line. (PR)
    | Comment!
  • Feb. 14, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 7:01 AM
    Watson Pharmaceuticals (WPI) seeks FDA approval to market generic Beyaz after facing a lawsuit from Bayer (BAYRY.PK) challenging a patent on the drug. The firm says it believes that it may be a "first applicant" to file an ANDA for the generic version of Beyaz and should be entitled to 180 days of generic market exclusivity.
    | Comment!
  • Feb. 10, 2012, 2:58 PM
    Watson Pharmaceuticals (WPI -0.2%) faces a lawsuit from Bayer (BAYRY.PK) over accusations that it violated the drug maker's birth control patents, according to Bloomberg.
    | Comment!
  • Feb. 3, 2012, 9:52 AM
    Watson Pharmaceuticals (WPI -0.6%) responds to increasing investment chatter over a Lipoderm patent challenge with a rather tepid statement that says the drug is still on track. The firm reiterates its view that it will land tentative FDA approval before July 15.
    | Comment!
  • Jan. 26, 2012, 10:17 AM
    Momenta Pharmaceuticals (MNTA -21.3%) plummets on heavy volume, reacting to reports that Watson Pharmaceuticals (WPI +1.6%) partner Amphastar won an appeals court stay involving its generic Lovenox blood thinner treatment. A preliminary injunction preventing the launch of a generic version of Lovenox had been granted in October.
    | Comment!
  • Jan. 25, 2012, 1:46 PM
    Watson Pharmaceuticals (WPI +2.8%) gets a lift from a Morgan Stanley upgrade to Overweight, noting that potential earnings upside and a higher valuation could drive the shares up 16% or more.
    | Comment!
  • Jan. 24, 2012, 11:24 AM
    Canaccord Genuity weighs in on Columbia Laboratories (CBRX +2.2%) after the firm was rocked by a FDA rejection of its preterm birth prevention gel. Though analyst Randall Stanicky acknowledges the "disappointment," he still sees potential for CBRX and rival Watson Pharmaceuticals (WPI -3.4%) on possible M&A activity and the under-leveraged balance sheets the firms carry.
    | Comment!
  • Jan. 24, 2012, 6:48 AM
    Watson Pharmaceuticals (WPI) announces prelim FY11 EPS of $4.75-4.77 vs. $4.61 consensus, and FY11 revenue of $4.57B vs. $4.53B consensus. For FY12, the company sees EPS of $5.25-5.55 and revenue of $5.3B. (PR) (earlier)
    | Comment!
  • Jan. 24, 2012, 2:27 AM
    Watson Pharmaceuticals (WPI) agrees to buy Ascent Pharmahealth for A$375M ($396M), turning Watson into the fifth-largest generic pharmaceuticals firm in Australia and the largest in Singapore, while giving the company footholds in Malaysia, Hong Kong, Vietnam and Thailand. The deal will be immediately accretive to 2012 earnings.
    | Comment!
  • Jan. 23, 2012, 8:17 AM
    Columbia Labs (CBRX) -52.5% premarket after trading was suspended all day Friday following the FDA's negative vote on the company's Prochieve drug candidate. Partner Watson Pharmaceutials (WPI) is little changed after falling 3.5% on Friday. Rival K-V (KV.A) +1.9% after Friday's 9.3% gain.
    | Comment!
  • Jan. 17, 2012, 2:08 PM
    Shares of K-V Pharmaceutical (KV.A +16.9%) soar after rival Columbia Laboratories' preterm birth gel is deemed "not effective" by the FDA. Also showing some action related to the news is Watson Pharmaceuticals (WPI -2.6%).
    | Comment!
  • Jan. 6, 2012, 10:39 AM
    Sabrient Systems reveals its “Baker’s Dozen” list of 13 stocks to buy and hold through the calendar year: STX, WNR, OCN, WPI, UTHR, CLD, GSM, DAN, AGCO, DXPE, KRO, URI, ASCA. Sabrient's lists have easily outperformed the S&P in each of the past three years.
    | Comment!
  • Dec. 27, 2011, 2:54 PM
    Reuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO.
    | Comment!
Visit Seeking Alpha's
ACT vs. ETF Alternatives
Company Description
Actavis PLC specialty pharmaceutical company engaged in developing, manufacturing and distributing generic, brand and biosimilar products.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States